文献速递前列腺癌

系列多参数磁共振成像能否在前列腺癌主动监测中替代前列腺穿刺活检?——系统诊断准确性综述

Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review.
PubMed 文献 · Eur Urol Oncol · 2020-09-21

该系统综述纳入7项横断面研究共800例接受主动监测的前列腺癌患者,评估多参数磁共振成像(mp-MRI)诊断疾病进展的准确性。汇总病理进展率为27%,mp-MRI汇总敏感度0.61(95%CI 0.46-0.74)、特异度0.78(95%CI 0.54-0.91)。按进展患病率30%调整后,阳性预测值0.43(95%CI 0.39-0.46),阴性预测值0.81(95%CI 0.78-0.84)。结论认为当前证据水平下不能用mp-MRI替代前列腺活检,机构应内部审计其诊断性能。

要点

  • mp-MRI诊断进展敏感度0.61、特异度0.78,准确性不足以替代活检。
  • 按30%患病率调整,阳性预测值仅0.43,阴性预测值0.81。
  • 各机构mp-MRI诊断性能差异显著,应基于本地数据制定监测方案。

核心结论

  • 当前证据水平下,主动监测方案中不能用mp-MRI完全替代前列腺活检。
  • mp-MRI诊断性能存在显著机构间差异,各机构应内部审计其主动监测中的诊断表现。
  • 主动监测方案应基于本地诊断性能,而非直接套用国际方案。

研究设计与样本

  • 系统诊断准确性综述,遵循Cochrane手册和PRISMA声明。
  • 纳入评估mp-MRI(指数试验)对比系统穿刺、靶向穿刺或模板穿刺(参考标准)诊断疾病进展的横断面研究。
  • 共纳入7项研究、800例接受主动监测的前列腺癌患者。
  • 使用STATA的metandi和midas命令进行荟萃分析。

主要发现

  • 汇总病理进展率为27%。
  • mp-MRI诊断疾病进展的汇总敏感度为0.61(95%CI 0.46-0.74),汇总特异度为0.78(95%CI 0.54-0.91)。
  • 按进展患病率30%调整后,阳性预测值为0.43(95%CI 0.39-0.46),阴性预测值为0.81(95%CI 0.78-0.84)。
  • 观察到显著异质性,meta回归分析未发现显著离群值。

临床怎么用

  • 临床不应以mp-MRI完全替代主动监测中的前列腺活检。
  • 各机构应基于本地mp-MRI诊断性能数据制定主动监测方案。
  • 国际主动监测方案在个体机构可能适用性有限,需结合本地实践调整。

局限性

  • 纳入研究间存在显著异质性。
  • 仅纳入7项研究,证据体量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The role of multiparametric magnetic resonance imaging (mp-MRI) during active surveillance (AS) of prostate cancer needs evaluation. It remains unclear whether mp-MRI can replace prostate biopsies completely during AS. OBJECTIVE: To evaluate the diagnostic performance of mp-MRI for disease progression in men on AS for prostate cancer. EVIDENCE ACQUISITION: This systematic review was performed in accordance with the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Cross-sectional studies that evaluate the diagnostic performance of mp-MRI (index test) for disease progression compared with systematic and targeted prostate/template biopsies or a composite of this (reference standard) were included. A meta-analysis was performed using STATA with "metandi" and "midas" commands. EVIDENCE SYNTHESIS: Seven studies with 800 patients were included in this systematic review. The pooled pathological progression rate was 27%. The pooled sensitivity and specificity of mp-MRI for disease progression were 0.61 (95% confidence interval [CI]: 0.46-0.74) and 0.78 (95% CI: 0.54-0.91), respectively. Adjusting for a prevalence of disease progression of 30% results in a positive predictive value of 0.43 (95% CI: 0.39-0.46) and a negative predictive value of 0.81 (95% CI: 0.78-0.84). Significant heterogeneity was observed. The meta-regression analysis did not demonstrate any significant outliers. CONCLUSIONS: It is not possible to supplant prostate biopsies with mp-MRI in AS protocols with the current level of evidence. There is significant institutional variation in the diagnostic performance of mp-MRI during AS. Institutions must internally audit the diagnostic performance of mp-MRI in the AS setting. AS protocols must be based on local diagnostic performance, rather than on international AS protocols that may have limited applicability at individual settings. PATIENT SUMMARY: In this review, we explored the accuracy of multiparametric magnetic resonance imaging in diagnosing disease progression for patients who were enrolled in active surveillance programmes for prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hettiarachchi D, Geraghty R, Rice P, et al. Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?-A Systematic Diagnostic Test Accuracy Review. Eur Urol Oncol. 2020. PMID: 32972894. doi:10.1016/j.euo.2020.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。